Latest News
Pharvaris reports Phase 3 success for deucrictibant XR in HAE prophylaxis
8 September 2026 - Pharvaris NV (NASDAQ: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists for bradykinin-mediated angioedema, on Tuesday announced positive top-line results from its CHAPTER-3 pivotal Ph...
Sky Labs presents clinical research outcomes for ring-type blood pressure monitor CART
8 September 2026 - Sky Labs, a South Korea-based medical technology company, announced on Monday that it has shared clinical research outcomes of its ring-type blood pressure monitor, CART, at ESC Congress 2026 in Munich, Germany.Sky Labs hosted five...
PT Prodia Diacro Laboratories receives Southeast Asian CRO Customer Value Leadership recognition from Frost & Sullivan
8 September 2026 - Market research and business consulting firm Frost & Sullivan announced on Tuesday that Indonesia-based PT Prodia Diacro Laboratories (Prodia the CRO) has received the 2026 Southeast Asian Customer Value Leadership Recognition ...
CorrectSequence Therapeutics reports new research showing tBE-mediated base editing therapy achieves durable remission in SCD and TDT across different genetic backgrounds
8 September 2026 - Clinical-stage biotech company CorrectSequence Therapeutics (Correctseq) announced on Tuesday that new research published online in the journal Cell Stem Cell demonstrates that CS-101/CS-206 base-editing therapy, developed with the...
Etcamah–CDK4/6 inhibitor combination approved in US for ESR1-mutated HR-positive breast cancer
7 September 2026 - Biopharmaceutical company AstraZeneca PLC (STO: AZN; LON: AZN; NYSE: AZN) said on Monday that US regulators have granted accelerated approval for Etcamah (camizestrant), its next-generation oral selective oestrogen receptor degrade...